Xenon Pharmaceuticals Quarterly Income Statement
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xenon Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Xenon Pharmaceuticals generated $0 in revenue, up 0.0% from the same quarter a year earlier. Xenon Pharmaceuticals reported a net loss of $110.7 million, compared with a loss of $84.7 million a year earlier. Diluted earnings per share came in at -$1.11.
Summary generated from market data by MetaCap's automated system. Methodology
Xenon Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 7.50M | 0 | 0 | 0 | 0 | — | — |
| Revenue growth (YoY) | — | -100.00% | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 123.16M | 112.33M | 109.77M | 96.34M | 94.23M | 80.24M | 77.48M | 73.68M | 69.10M | 59.04M | 53.70M | 55.68M |
| Research & Development | 99.22M | 88.51M | 87.70M | 77.05M | 74.98M | 61.20M | 59.47M | 56.97M | 49.70M | 44.25M | 41.08M | 42.88M |
| Operating Income | -123.16M | -112.33M | -109.77M | -96.34M | -94.23M | -72.74M | -77.48M | -73.68M | -69.10M | -59.04M | -53.70M | -55.68M |
| Other Income (Expense) | 11.83M | 7.46M | 5.04M | 6.12M | 8.90M | 8.12M | 7.94M | 10.57M | 10.85M | 11.52M | 8.75M | 7.07M |
| Pretax Income | -111.32M | -104.87M | -104.72M | -90.22M | -85.33M | -64.62M | -69.53M | -63.11M | -58.26M | -47.52M | -44.95M | -48.62M |
| Income Tax | -585.00K | -2.57M | 538.00K | 677.00K | -626.00K | 427.00K | -3.85M | -320.00K | -333.00K | 412.00K | -205.00K | -157.00K |
| Net Income | -110.74M | -102.30M | -105.26M | -90.90M | -84.71M | -65.05M | -65.69M | -62.79M | -57.92M | -47.93M | -44.74M | -48.46M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.11 | -1.17 | -1.31 | -1.15 | -1.07 | -0.83 | -0.83 | -0.81 | -0.75 | -0.62 | -0.65 | -0.73 |
| EPS (Diluted) | -1.11 | -1.17 | -1.31 | -1.15 | -1.07 | -0.83 | -0.83 | -0.81 | -0.75 | -0.62 | -0.65 | -0.73 |
| Shares Outstanding (Basic) | 99.61M | 87.35M | — | 79.25M | 78.95M | 78.69M | — | 77.93M | 77.67M | 77.59M | — | 66.00M |
| Shares Outstanding (Diluted) | 99.61M | 87.35M | — | 79.25M | 78.95M | 78.69M | — | 77.93M | 77.67M | 77.59M | — | 66.00M |
| EBITDA | -122.60M | -111.74M | -109.16M | -95.69M | -93.60M | -72.08M | -76.81M | -73.01M | -68.46M | -58.45M | -54.32M | -53.95M |
| Operating Margin | — | — | — | — | — | -969.84% | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | -867.29% | — | — | — | — | — | — |
This table shows 12 quarterly periods of Xenon Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow XENE's reporting calendar. What is a income statement?